EPO patent dispute
Executive Summary
Massachusetts District Court preliminarily rules that Amgen's human recombinant erythropoetin infringes Genetics Institute's patent relating to recombinant DNA production of the substance. Judge William Young said at a Feb. 24 hearing that he would grant the motion of Genetics Institute and Chugai Pharmaceuticals for summary judgment that Amgen infringes their patent. Amgen said it does not plan to "change our strategy with respect to development of human recombinant erythropoeitin" and reiterated its position that Genetics Institute and Chugai are infringing its patent.